DEVELOPMENT OF A DIAGNOSTIC AND TREATMENT ALGORITHM FOR DIFFERENTIATED THYROID CANCER BASED ON THE APPLICATION OF MOLECULAR-GENETIC ANALYSIS METHODS
Keywords:
standardization, dentistry, patient management protocolAbstract
The study evaluated the frequency and clinicopathological significance of BRAF-V600E, RET/PTC, TERT, RAS, and PAX8-PPAR-γ mutations in 300 patients with differentiated thyroid cancer (DTC). The patients were examined at the Tashkent City Branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology between 2014 and 2024. All patients underwent cytology according to the Bethesda system, ultrasound stratification based on TI-RADS, and molecular analyses using PCR and FISH methods. The BRAF-V600E mutation was predominantly detected in papillary carcinoma (82.9%) and was associated with unfavorable TNM characteristics; RET/PTC occurred exclusively in PTC (100%); TERT was more frequent in the follicular type (46.2%); and RAS and PAX8-PPAR-γ mutations were observed only in FTC. The correlation with ultrasound features was weak. The findings confirm the importance of molecular genetic testing in DTC for improving prognostic accuracy and personalizing treatment strategies.
References
Tillyashaykhov M.N., Ibragimov Sh.N., Janklich S.M. The State of Oncological Care for the Population of the Republic of Uzbekistan in 2019 // “Fan” Publishing House. – 2020. (in Russ).
Califano I, Smulever A, Jerkovich F, Pitoia F. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. Rev Endocr Metab Disord 2023.
Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M. PD- 1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol 2020; 38: 2620-2627.
Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg 2020; 9: S28-S42.
Gouda MA, Subbiah V. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book 2023; 43: e404770.
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20: 925-951.
Hwang Y, Yun HJ, Jeong JW, Kim M, Joo S, Lee HK, Chang HS, Kim SM, Fang S. Co-inhibition of glutaminolysis and one-carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer. Cell Death Dis 2023; 14: 515.
Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, Deschamps F, Lamartina L, Lacroix L, Dupuy C, Baudin E, Do Cao C, Hadoux J. Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel) 2022; 14.
La Vecchia C., Malvezzi M., Bosetti C., et. al. Thyroid Cancer Mortality and Incidence: A Global Overview. Int. J. Cancer. 2015; 136:2187–2195.
Pellegriti G, Frasca F, Regalbuto C, et. al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
Siegel R.L., Miller K.D., Fuchs H.E., A.Jemal Cancer statistics, 2021 CA Cancer J. Clin., 2021:71(1):7-33.
Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2019. CA Cancer J. Clin. 2019;69:7–34.
Turkmen E, Sogutlu F, Erdogan M, Biray Avci C. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle. Med Oncol. 2023; 40: 196.
Alkhathami, A. G., Altalbawy, F. M. A., Rizaev, J. A., Jeddoa, Z. M. A., & Jabir, M. S. (2025). An overview of lncRNA GAPLINC's role in human cancer growth and metastasis. Archives of Biochemistry and Biophysics, 110506.
Irgashev, K. N., & Rizaev, J. A. (2025). Optimization of clinical outcomes in the rehabilitation of patients with non-caries dental lesions manifesting as pathological abrasion. Medical Research Journal, 1(1), 146–151.
Shakhanova, S. S., Abdurakhmonov, J. A., & Rakhimov, N. M. (2023). Targeted therapy in the palliative treatment of platinum-resistant recurrent ovarian cancer complicated by ascites. The American Journal of Medical Sciences and Pharmaceutical Research, 5(8), 1.
Rizaev, J. A., Rahimov, N. M., & Shakhanova, S. S. (2023). Prostate cancer morbidity and mortality among men in high-risk areas. Eurasian Medical Research Periodical, 18, 101–104.
